U.S. markets closed
  • S&P 500

    3,699.12
    +32.40 (+0.88%)
     
  • Dow 30

    30,218.26
    +248.74 (+0.83%)
     
  • Nasdaq

    12,464.23
    +87.05 (+0.70%)
     
  • Russell 2000

    1,892.45
    +43.75 (+2.37%)
     
  • Crude Oil

    46.09
    +0.45 (+0.99%)
     
  • Gold

    1,842.00
    +0.90 (+0.05%)
     
  • Silver

    24.32
    +0.18 (+0.76%)
     
  • EUR/USD

    1.2127
    -0.0022 (-0.18%)
     
  • 10-Yr Bond

    0.9690
    +0.0490 (+5.33%)
     
  • GBP/USD

    1.3438
    -0.0015 (-0.11%)
     
  • USD/JPY

    104.1400
    +0.2800 (+0.27%)
     
  • BTC-USD

    18,793.04
    -28.97 (-0.15%)
     
  • CMC Crypto 200

    365.19
    -14.05 (-3.71%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Illumina: Q3 Earnings Insights

Benzinga Insights
·1 min read

Shares of Illumina (NASDAQ:ILMN) were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were down 47.15% over the past year to $1.02, which beat the estimate of $0.77.

Revenue of $794,000,000 decreased by 12.46% from the same period last year, which beat the estimate of $715,910,000.

Guidance

Illumina hasn't issued any earnings guidance for the time being.

Illumina hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Oct 29, 2020

View more earnings on ILMN

Time: 05:00 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.illumina.com%2F&eventid=2625170&sessionid=1&key=B84631F84739005A09FC0BC17A1049DB&regTag=&sourcepage=register

Technicals

Company's 52-week high was at $404.20

52-week low: $196.78

Price action over last quarter: down 12.56%

Company Description

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 17% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.